Drugmakers plan to raise U.S. prices on at least 350 branded medications beginning Jan. 1, including treatments for cancer, COVID-19 and RSV, according to data provided exclusively to Reuters by healthcare research firm 3 Axis Advisors.
The number of increases is up from 250 announced at the same point last year. The median list price increase is around 4%, in line with 2025. The changes do not reflect rebates or discounts negotiated with payers.
Pfizer announced the most price hikes, affecting about 80 medications, including COVID-19 vaccine Comirnaty, which will rise by 15%, and hospital-administered drugs such as morphine and hydromorphone, some of which will see fourfold increases. GSK plans hikes of 2% to 8.9% on about 20 drugs and vaccines. Sanofi and Novartis are also among the companies raising prices.
Boehringer Ingelheim and Eli Lilly plan to cut prices on around nine drugs, including a more than 40% reduction for Type 2 diabetes drug Jardiance and three related treatments. Jardiance is among the 10 medications with Medicare-negotiated prices for 2026, which slashed its cost by two-thirds.
The pricing moves come amid pressure from the Trump administration to lower costs. Several companies striking deals with the administration — including Pfizer, Sanofi, Boehringer Ingelheim, Novartis and GSK — are still moving ahead with price increases in the new year.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
